LA Law Firm (Legal Alliance) has been named “Competition Law Firm of the Year in Ukraine” according to the Corporate Intl Magazine Global Award.
We have handled antitrust and competition matters in almost every industry where they arise, including our key industry sectors.
Legal Alliance is proud to be legal counselor in several landmark cases in the sphere of competition on pharmaceutical market such as investigations of the Antimonopoly Committee of Ukraine regarding distributors contracts and marketing agreements with pharmacies.
OUR SERVICES
Dominant Position:
Concerted actions:
Unfair Competition:
Concentrations:
Public Procurement:
Investigations of the AMCU:
Competition Compliance:
OUR EXPERIENCE
LANDMARK CASES
Marketing agreements with pharmacies
Agreements concluded between medicinal products’ manufacturers (their representatives) and pharmacies are considered by the Antimonopoly Committee of Ukraine (AMCU) as those with a high possibility to possess the signs of anticompetitive concerted actions. It is worth to mention that the service rendering agreements between the manufacturer and the entity that carries out the further sale of the manufacturer’s goods (so-called vertical agreements) are deemed as risky not only in Ukraine, but also in other countries, in particular in the European Union countries. However, in the European Union countries there are more clear recommendations of the competition authorities in relation to such agreements, allowing market participants to carry out the promotion of their products and be competitive with respect to security risks.
The AMCU position regarding the majority of marketing agreements issues is not yet finalized. Approaches that have been set out in the AMCU’s recommendations and provided to many pharmacy chains and suppliers of medicinal products are very conservative.
The most problematic issues in these agreements are the following:
Currently, the AMCU takes the position that, generally, the establishment of these conditions bears the evidence of anticompetitive concerted actions. We are of the opinion that this position is controversial.
In the nearest future, we expect more activities from the AMCU’s territorial departments on this matter.
In case the AMC qualifies the marketing agreement as anticompetitive concerted actions, the participants of such concerted action may be subject to a fine in the amount up to 10% of income (revenue) from the products sales for the year preceding the year in which the fine is imposed.
In April 2016, we gained a unique experience in this field. We managed to negotiate with the AMCU a marketing agreement with the pharmacy belonging to one of our Clients. Please refer to our web-site for the official press-release on this matter.
Within the framework of the completed project on marketing agreement coordination with the AMCU, we managed to convince the AMCU that the establishment of the above-mentioned risk conditions does not lead to the violation of the competition in the market.
In addition to this project, our experts successfully fulfilled 7 projects regarding the drafting and implementation of marketing agreements with pharmacies.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
Almost UAH 5 billion. This is the total amount of the fine imposed by the Antimonopoly Committee of Ukraine (AMCU) in its decision No. 370-r dated 31.07.2025 on
Key changes: The government has clarified the 20% sales quota for medicinal products and tightened requirements for pharmacy chains.
The Legal Practice publishing house has announced the release of the twenty-second issue of Ukrainian Law Firms. A Handbook for Foreign Clients.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
Almost UAH 5 billion. This is the total amount of the fine imposed by the Antimonopoly Committee of Ukraine (AMCU) in its decision No. 370-r dated 31.07.2025 on
Key changes: The government has clarified the 20% sales quota for medicinal products and tightened requirements for pharmacy chains.